What this means
This is a plan for a study that has not reported results yet. It will compare drug, surgery, and diet ways of losing weight, and track lifespan and other health measures.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 35–65 · 150 adults with metabolic syndrome planned; study is currently recruiting
- Where
- 1 site
The science
- Registered title
- Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
- Trial ID
- NCT06410352 ↗
- Phase
- PHASE 4
- Study type
- interventional
- Conditions
- Metabolic Syndrome
- What is tested
- Semaglutide, Empagliflozin, Minigastric bypass, Analimentary detoxication, Ramadan fast's weight loss
- Sponsor
- University Medical Center, Kazakhstan
- Ages
- 35 Years to 65 Years
- Dates
- First posted May 13, 2024 · updated Nov 26, 2025
Registry summary
Background. The prevalence of type 2 diabetes mellitus (T2D) in the world is constantly increasing. Treatment of T2D is complicated by arterial hypertension and obesity (metabolic syndrome - MS). Cardiovascular complications are the main cause of death in patients with MS. Objective weight loss improves clinical and laboratory parameters in patients with T2D and hypertension.
Purpose: To study lifespan, glycemic and lipid metabolism, quality of life, and cost-effectiveness of pharmacologic, surgical, and dietetic weight loss methods in obese patients with MS at 24 weeks in a comparative clinical trial.
Methods:
- st stage - Study design: An open pilot prospective clinical trial. The study included 71 adult patients with T2D and hypertension for the Ramadan fast's (RF) weight loss.
- nd stage - Study design: A 24-week open label, prospective, multicenter, comparative clinical trial with the intention-to-treat analysis.
Participants. Totally 150 adult patients with MS aged 35-65 years and with BMI≥27 kg/m2 for Asian will be included. They will be distributed in three comparative groups: drug treatment, surgery and diet.
Primary endpoints: weight loss, fasting blood glucose, blood insulin level, systolic/diastolic BP.
Secondary endpoints: blood lipids, heel bone mineral density (HBMD), and ejection fraction (EF).
Expected results:
A prospective multicenter clinical study will provide comparative results on life expectancy, glycemic and lipid metabolism, quality of life, cost-effectiveness of pharmacological, bariatric and dietary methods of weight loss in patients with obesity, T2D and hypertension. As a result of the research, the following will be published:
- at least three articles and/or reviews in peer-reviewed scientific publications indexed in the Science Citation Index Expanded of the Web Of Science database and/or having a Cite Score percentile in the Scopus of at least 50;
- at least 1 patent for an invention (including a positive decision on it).
Sites (1)
- Kuat Pernekulovich Oshakbayev, Astana, Astana, Kazakhstan